Dekang Medical has been selected as the first company to participate in the FDA's Digital Health Device Pilot Program.
Golden Finance, July 23 — Continuous blood glucose monitoring device manufacturer Dexcom Medical has been selected by the U.S. FDA as the first company to participate in the TEMPO digital health device pilot project. The TEMPO project aims to evaluate new digital health technologies that help improve chronic disease management and provide real-world data. Dexcom Medical will implement an AI-driven blood glucose health program, combining data from Dexcom G7 and Stelo devices with contextual health information such as nutrition, physical activity, sleep, and stress, in order to provide more personalized insights for healthcare professionals and eligible users.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Why do tech stocks become "cheaper as they rise"? 80% profit surge supports valuations, but if AI expectations fall short, they will instantly become expensive.
In a bear market, it is usually necessary to smash stock prices to pieces with a hammer to make stocks cheaper. However, technology stocks have found another path.
EUR/JPY Price Forecast: Tests rising wedge bottom near 184.00
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Crypto prices
More
